GH Research PLC

General ticker "GHRS" information:

  • Sector: Health Care
  • Industry: Pharmaceuticals
  • Capitalization: $665.0M (TTM average)

GH Research PLC follows the US Stock Market performance with the rate: 37.8%.

Estimated limits based on current volatility of 3.2%: low 14.15$, high 15.09$

Factors to consider:

  • Total employees count: 14 as of 2021
  • Current price 40.6% above estimated high
  • Earnings for 9 months up through Q3 exceed our estimates

Stock Forecast*

* forecast is subjective and experimental, should not be used for any investment decisions

Long term estimates were made for the period from 2024-12-31 to 2026-12-31

  • 2024-12-31 to 2025-12-31 estimated range: [4.60$, 10.92$]
  • 2025-12-31 to 2026-12-31 estimated range: [4.43$, 10.44$]

Financial Metrics affecting the GHRS estimates:

  • Negative: with PPE of -9.6 at the end of fiscal year the price was high
  • Negative: negative Operating income
  • Negative: Operating cash flow per share per price, % of -11.31 <= 0.33
  • Positive: Investing cash flow per share per price, % of 17.43 > -0.66
  • Negative: negative Industry operating cash flow (median)
  • Positive: Shareholder equity ratio, % of 95.05 > 63.39

Similar symbols

Short-term GHRS quotes

Long-term GHRS plot with estimates

Financial data

YTD 2023-12-31 2024-12-31
Operating Revenue $0.00MM $0.00MM
Operating Expenses $41.22MM $50.31MM
Operating Income $-41.22MM $-50.31MM
Non-Operating Income $5.63MM $11.35MM
Interest Expense $0.72MM $0.72MM
R&D Expense $29.82MM $35.02MM
Income(Loss) $-35.59MM $-38.96MM
Profit(Loss)* $-35.59MM $-38.96MM
Stockholders Equity $218.97MM $178.95MM
Assets $226.30MM $188.27MM
Operating Cash Flow $-33.34MM $-42.28MM
Capital expenditure $0.10MM $0.05MM
Investing Cash Flow $-54.10MM $65.14MM
Financing Cash Flow $-0.20MM $-0.30MM
Earnings Per Share** $-0.68 $-0.75

* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.